The clinical effects of inclisiran, a first-in-class LDL-C lowering siRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia

Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial

(2023) Kausik K Ray et al.   Lancet Diabetes & Endocrinology

Evaluation of the distribution and excretion of [14C]-inclisiran following single subcutaneous administration in cynomolgus monkeys

(2022) Dario Lehoux et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Atherosclerotic Cardiovascular Disease Risk and Lipid-Lowering Therapy Requirement in China

(2022) Lei Bi et al.   Frontiers in Cardiovascular Medicine

Clinical Pharmacology of RNA Interference–Based Therapeutics: A Summary Based on Food and Drug Administration–Approved Small Interfering RNAs

(2022) Xing Jing et al.   DRUG METABOLISM AND DISPOSITION

The growth of siRNA-based therapeutics: updated clinical studies

(2021) M. May Zhang et al.   BIOCHEMICAL PHARMACOLOGY

Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1

(2021) Yaacov Frishberg et al.   Clinical Journal of the American Society of Nephrology

Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol

(2020) Kausik K. Ray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Single‐Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N‐acetylgalactosamine–Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects

(2020) Bahru A. Habtemariam et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria

(2020) Manisha Balwani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of China’s Low Centralized Medicine Procurement Prices on the Cost-Effectiveness of Statins for the Primary Prevention of Atherosclerotic Cardiovascular Disease

(2020) Miao Wang et al.   Global Heart

Genetic Inhibition of PCSK9 and Liver Function

(2020) Antoine Rimbert et al.   JAMA Cardiology

Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria

(2019) Eliane Sardh et al.   NEW ENGLAND JOURNAL OF MEDICINE

Current Trends in Non-HDL-Cholesterol and LDL-Cholesterol Levels in Adults with Atherosclerotic Cardiovascular Disease

(2019) Gloria Lena Vega et al.   Journal of Clinical Lipidology

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

(2019) François Mach et al.   EUROPEAN HEART JOURNAL

Small Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9

(2019) Charles A. German et al.   BIODRUGS

Inclisiran—New hope in the management of lipid disorders?

(2019) Krzysztof Dyrbuś et al.   Journal of Clinical Lipidology

Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies

(2019) R. Scott Wright et al.   MAYO CLINIC PROCEEDINGS

Prevalence of dyslipidemia and achievement of low-density lipoprotein cholesterol targets in Chinese adults: A nationally representative survey of 163,641 adults

(2018) Mei Zhang et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories

(2018) Kyle J Foreman et al.   LANCET

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

(2017) Brian A. Ference et al.   EUROPEAN HEART JOURNAL

Oligonucleotide Therapeutics — A New Class of Cholesterol-Lowering Drugs

(2017) Anastasia Khvorova   NEW ENGLAND JOURNAL OF MEDICINE

Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

(2017) Kausik K. Ray et al.   NEW ENGLAND JOURNAL OF MEDICINE

No evidence to support high-intensity statin in Chinese patients with coronary heart disease

(2016) Wen Dai et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Global Overview of the Epidemiology of Atherosclerotic Cardiovascular Disease

(2015) Simon Barquera et al.   ARCHIVES OF MEDICAL RESEARCH

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial

(2015) Christopher P. Cannon et al.   EUROPEAN HEART JOURNAL

Anti-PCSK9 Monotherapy for Hypercholesterolemia

(2014) Michael J. Koren et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY